FIMO Health

The Team

Teamname: FIMO Health

Founders: Alexander Krawinkel, Dominik Stiegeler, Benedict Höger

FIMO a digital solution for people with chronic fatigue

People with diseases such as cancer, multiple sclerosis or myalgic encephalomyelitis often suffer from fatigue, massively affecting their quality of life. Depending on the severity of the disease, the vital capacity can drop to as little as 10% of the original performance level. Fatigue is a clinically relevant exhaustion that is not significantly improved by sleep or relaxation and occurs in disproportion to previous cognitive or physical activity.

We are developing a data-based solution for fatigue patients. Using various devices, we measure important vital parameters (pulse, HRV, sleep, etc.) and environmental parameters (light, noise, weather, etc.) of the patients. In addition, our app includes various questionnaires and cognitive tests that are completed by the patients.

Using this everyday data and artificial intelligence, we want to help individuals to gain a better understanding of their individual fatigue and to avoid exceeding their own stress limits in order to reduce fatigue. In addition, we want to demonstrate and track the benefits and effectiveness of various therapies and medications.

We are a spin-off of the University of Cologne and also work with other research partners such as the University of Bonn or the University of Witten-Herdecke as well as with partners in industry such as Merck or Samsung. Currently, we are conducting a clinical trial with MS patients to test and further develop our prototype.

About the research project

As part of the Start-Up Transfer NRW program, Fimo MS App is developing an app at the University Hospital of Cologne, which will diagnose Long Covid. The app is designed to help those affected and those treating the patient in the context of the current pandemic.

Based on heart rate variability (HRV) and other data provided by affected persons in the app, the Fimo MS app develops mechanisms to diagnose long covid disease. In Germany alone, there are an estimated 300,000 people affected by Long Covid as a result of Covid-19 disease.

The process leading up to diagnosis can be very arduous for many people affected, and it is also difficult for those treating them, as there are not yet any objectively comprehensible criteria for making a diagnosis, which is where the app can help. The app will then be available either as a stand-alone product or as an option for software integration into other existing apps (SDK).

The product, which is funded by the European Regional Development Fund (ERDF), is currently being developed and should be available at the end of the research project.